Targeting carcinogen metabolism by dietary cancer preventive compounds

Current Cancer Drug Targets

Volumn 7, Issue 5, 2007, Pages 416-424

  Yu, Siwang ^a   Kong, Ah Ng ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Dietary cancer preventive compounds; Metabolizing enzymes; Nrf2; Nuclear receptors; Phytochemicals; Polymorphism; Transporters

Indexed keywords

ANTIOXIDANT; AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; FLAVONOID; ISOTHIOCYANIC ACID DERIVATIVE; PREGNANE X RECEPTOR; QUERCETIN; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR NRF2; XENOBIOTIC AGENT;

ANTIOXIDANT RESPONSIVE ELEMENT; CANCER; CANCER PREVENTION; CANCER RISK; DIET THERAPY; ENZYME ACTIVATION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR THERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVIEW; XENOBIOTIC METABOLISM;

ANIMALS; CARCINOGENS; DIET; HUMANS; NEOPLASMS; XENOBIOTICS;

EID: 34547575782     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907781386669     Document Type: Review

References (145)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics, 2006. CA Cancer J. Clin. 2006, 56, 106-130.
2. Barrett, J. C. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ. Health Perspect. 1993, 100, 9-20.
3. Carbone, M.; Pass, H. I. Multistep and multifactorial carcinogenesis: when does a contributing factor become a carcinogen? Semin. Cancer Biol. 2004, 14, 399-405.
4. Seymour, J. D.; Calle, E. E.; Flagg, E. W.; Coates, R. J.; Ford, E. S.; Thun, M. J. Diet Quality Index as a predictor of short-term mortality in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Am. J. Epidemiol. 2003, 157, 980-988.
5. Surh, Y. J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768-780.
6. Melczer, N.; Hamar, M. Studies on the Stages of Chemical Carcinogenesis. Oncology 1964, 18, 195-209.
7. Wattenberg, L. W. Chemoprevention of cancer. Cancer Res. 1985, 45, 1-8.
8. Meyer, U. A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm. 1996, 24, 449-459.
9. Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28, 249-268.
10. Anders, M. W. Glutathione-dependent bioactivation of haloalkanes and haloalkenes. Drug Metab. Rev. 2004, 36, 583-594.
11. Guengerich, F. P. Metabolism of chemical carcinogens. Carcinogenesis 2000, 21, 345-351.
12. Ross, M. K.; Pegram, R. A. In vitro biotransformation and genotoxicity of the drinking water disinfection byproduct bromodichloromethane: DNA binding mediated by glutathione transferase theta 1-1. Toxicol. Appl. Pharmacol. 2004, 195, 166-181.
13. van Iersel, M. L.; Verhagen, H.; van Bladeren, P. J. The role of biotransformation in dietary (anti)carcinogenesis. Mutat. Res. 1999, 443, 259-270.
14. Mandlekar, S.; Hong, J. L.; Kong, A. N. Modulation of metabolic enzymes by dietary phytochemicals: a review of mechanisms underlying beneficial versus unfavorable effects. Curr. Drug Metab. 2006, 7, 661-675.
15. Sheweita, S. A. Drug-metabolizing enzymes: mechanisms and functions. Curr. Drug Metab. 2000, 1, 107-132.
16. King, R. S.; Teitel, C. H.; Shaddock, J. G.; Casciano, D. A.; Kadlubar, F. F. Detoxification of carcinogenic aromatic and heterocyclic amines by enzymatic reduction of the N-hydroxy derivative. Cancer Lett. 1999, 143, 167-171.
17. Sogawa, K.; Fujii-Kuriyama, Y. Ah receptor, a novel ligand-activated transcription factor. J. Biochem. (Tokyo) 1997, 122, 1075-1079.
18. Denison, M. S.; Nagy, S. R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43, 309-334.
19. Tirona, R. G.; Kim, R. B. Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci. 2005, 94, 1169-1186.
20. Zhou, J.; Zhang, J.; Xie, W. Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases. Curr. Drug Metab. 2005, 6, 289-298.
21. Jeuken, A.; Keser, B. J.; Khan, E.; Brouwer, A.; Koeman, J.; Denison, M. S. Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J. Agric. Food Chem. 2003, 51, 5478-5487.
22. Han, E. H.; Kim, J. Y.; Jeong, H. G. Effect of biochanin A on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Arch. Pharm. Res. 2006, 29, 570-576.
23. Denison, M. S.; Pandini, A.; Nagy, S. R.; Baldwin, E. P.; Bonati, L. Ligand binding and activation of the Ah receptor. Chem. Biol. Interact. 2002, 141, 3-24.
24. Chen, I.; Safe, S.; Bjeldanes, L. Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem. Pharmacol. 1996, 51, 1069-1076.
25. MacDonald, C. J.; Ciolino, H. P.; Yeh, G. C. Dibenzoylmethane modulates aryl hydrocarbon receptor function and expression of cytochromes P50 1A1, 1A2, and 1B1. Cancer Res. 2001, 61, 3919-3924.
26. Ciolino, H. P.; Daschner, P. J.; Wang, T. T.; Yeh, G. C. Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem. Pharmacol. 1998, 56, 197-206.
27. Gradelet, S.; Astorg, P.; Leclerc, J.; Chevalier, J.; Vernevaut, M. F.; Siess, M. H. Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobiotic-metabolizing enzymes in the rat. Xenobiotica 1996, 26, 49-63.
28. Stephensen, P. U.; Bonnesen, C.; Schaldach, C.; Andersen, O.; Bjeldanes, L. F.; Vang, O. N-methoxyindole-3-carbinol is a more efficient inducer of cytochrome P-450 1A1 in cultured cells than indol-3-carbinol. Nutr. Cancer 2000, 36, 112-121.
29. Chang, Y. C.; Riby, J.; Chang, G. H.; Peng, B. C.; Firestone, G.; Bjeldanes, L. F. Cytostatic and antiestrogenic effects of 2-(indol-3-ylmethyl)- 3,3′-diindolylmethane, a major in vivo product of dietary indole-3-carbinol. Biochem. Pharmacol. 1999, 58, 825-834.
30. Allen, S. W.; Mueller, L.; Williams, S. N.; Quattrochi, L. C.; Raucy, J. The use of a high-volume screening procedure to assess the effects of dietary flavonoids on human cyp1a1 expression. Drug Metab. Dispos. 2001, 29, 1074-1079.
31. Moon, Y. J.; Wang, X.; Morris, M. E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. In vitro. 2006, 20, 187-210.
32. Ciolino, H. P.; Wang, T. T.; Yeh, G. C. Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affect cytochrome P450 1A1 activity. Cancer Res. 1998, 58, 2754-2760.
33. Lu, Y. F.; Santostefano, M.; Cunningham, B. D.; Threadgill, M. D.; Safe, S. Substituted flavones as aryl hydrocarbon (Ah) receptor agonists and antagonists. Biochem. Pharmacol. 1996, 51, 1077-1087.
34. Peryt, B.; Szymczyk, T.; Lesca, P. Mechanism of antimutagenicity of wheat sprout extracts. Mutat. Res. 1992, 269, 201-215.
35. Zhang, S.; Qin, C.; Safe, S. H. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ. Health Perspect. 2003, 111, 1877-1882.
36. Ciolino, H. P.; Yeh, G. C. The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor. Br. J. Cancer 1999, 79, 1340-1346.
37. Stresser, D. M.; Bjeldanes, L. F.; Bailey, G. S.; Williams, D. E. The anticarcinogen 3,3′-diindolylmethane is an inhibitor of cytochrome P-450. J. Biochem. Toxicol. 1995, 10, 191-201.
38. Zhai, S.; Dai, R.; Friedman, F. K.; Vestal, R. E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos. 1998, 26, 989-992.
39. Lee, C. K.; Fulp, C.; Bombick, B. R.; Doolittle, D. J. Inhibition of mutagenicity of N-nitrosamines by tobacco smoke and its constituents. Mutat. Res. 1996, 367, 83-92.
40. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J. Pharmacol. Exp. Ther. 1999, 290, 429-438.
41. Omura, T.; Sato, R. The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature. J. Biol. Chem. 1964, 239, 2370-2378.
42. Hodek, P.; Trefil, P.; Stiborova, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 2002, 139, 1-21.
43. Dai, R.; Jacobson, K. A.; Robinson, R. C.; Friedman, F. K. Differential effects of flavonoids on testosterone-metabolizing cytochrome P450s. Life Sci. 1997, 61, PL75-PL80.
44. Zuber, R.; Modriansky, M.; Dvorak, Z.; Rohovsky, P.; Ulrichova, J.; Simanek, V.; Anzenbacher, P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother. Res. 2002, 16, 632-638.
45. Shimada, T.; Yamazaki, H.; Foroozesh, M.; Hopkins, N. E.; Alworth, W. L.; Guengerich, F. P. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol. 1998, 11, 1048-1056.
46. Shou, M.; Grogan, J.; Mancewicz, J. A.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V.; Korzekwa, K.R. Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994, 33, 6450-6455.
47. Ciolino, H. P.; Daschner, P. J.; Yeh, G. C. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 1999, 340(Pt 3), 715-722.
48. Chen, C.; Kong, A. N. Dietary cancer-chemopreventive compounds: from signaling and gene expression to pharmacological effects. Trends Pharmacol. Sci. 2005, 26, 318-326.
49. Sheweita, S. A.; Tilmisany, A. K. Cancer and phase II drug-metabolizing enzymes. Curr. Drug Metab. 2003, 4, 45-58.
50. Nelson, C. P.; Kidd, L. C.; Sauvageot, J.; Isaacs, W. B.; De Marzo, A. M.; Groopman, J. D.; Nelson, W. G.; Kensler, T. W. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 2001, 61, 103-109.
51. Diah, S. K.; Smitherman, P. K.; Townsend, A. J.; Morrow, C. S. Detoxification of 1-chloro-2,4-dinitrobenzene in MCF7 breast cancer cells expressing glutathione S-transferase P1-1 and/or multidrug resistance protein 1. Toxicol. Appl. Pharmacol. 1999, 157, 85-93.
52. Henderson, C. J.; Smith, A. G.; Ure, J.; Brown, K.; Bacon, E. J.; Wolf, C. R. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc. Natl. Acad. Sci. USA 1998, 95, 5275-5280.
53. Long, D. J.; 2nd, Waikel, R. L.; Wang, X. J.; Perlaky, L.; Roop, D. R.; Jaiswal, A. K. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 2000, 60, 5913-5915.
54. Hung, H. C.; Chuang, J.; Chien, Y. C.; Chern, H. D.; Chiang, C. P.; Kuo, Y. S.; Hildesheim, A.; Chen, C. J. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol. Biomarkers Prev. 1997, 6, 901-905.
55. Saarikoski, S. T.; Voho, A.; Reinikainen, M.; Anttila, S.; Karjalainen, A.; Malaveille, C.; Vainio, H.; Husgafvel-Pursiainen, K.; Hirvonen, A. Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int. J. Cancer 1998, 77, 516-521.
56. Srivastava, D. S.; Mishra, D. K.; Mandhani, A.; Mittal, B.; Kumar, A.; Mittal, R. D. Association of genetic polymorphism of glutathione S-transferase M1, T1, P1 and susceptibility to bladder cancer. Eur. Urol. 2005, 48, 339-344.
57. Risch, A.; Wallace, D. M.; Bathers, S.; Sim, E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum. Mol. Genet. 1995, 4, 231-236.
58. Conney, A. H. Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman Lecture. Cancer Res. 2003, 63, 7005-7031.
59. Prestera, T.; Holtzclaw, W. D.; Zhang, Y.; Talalay, P. Chemical and molecular regulation of enzymes that detoxify carcinogens. Proc. Natl. Acad. Sci. USA 1993, 90, 2965-2969.
60. Dinkova-Kostova, A. T.; Massiah, M. A.; Bozak, R. E.; Hicks, R. J.; Talalay, P. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups. Proc. Natl. Acad. Sci. USA 2001, 98, 3404-3409.
61. Rushmore, T. H.; Morton, M. R.; Pickett, C. B. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J. Biol. Chem. 1991, 266, 11632-11639.
62. Rushmore, T. H.; King, R. G.; Paulson, K. E.; Pickett, C. B. Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc. Natl. Acad. Sci. USA 1990, 87, 3826-3830.
63. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; Yamamoto, M.; Nabeshima, Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 1997, 236, 313-322.
64. Nioi, P.; McMahon, M.; Itoh, K.; Yamamoto, M.; Hayes, J. D. Identification of a novel Nrf2-regulated antioxidant response element (ARE) in the mouse NAD(P)H:quinone oxidoreductase 1 gene: reassessment of the ARE consensus sequence. Biochem. J. 2003, 374, 337-348.
65. Zhu, M.; Fahl, W. E. Functional characterization of transcription regulators that interact with the electrophile response element. Biochem. Biophys. Res. Commun. 2001, 289, 212-219.
66. Katoh, Y.; Itoh, K.; Yoshida, E.; Miyagishi, M.; Fukamizu, A.; Yamamoto, M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 2001, 6, 857-868.
67. Venugopal, R.; Jaiswal, A. K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. USA 1996, 93, 14960-14965.
68. Chan, K.; Kan, Y. W. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. USA 1999, 96, 12731-12736.
69. Ramos-Gomez, M.; Kwak, M. K.; Dolan, P. M.; Itoh, K.; Yamamoto, M.; Talalay, P.; Kensler, T. W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. USA 2001, 98, 3410-3415.
70. Xu, C.; Huang, M. T.; Shen, G.; Yuan, X.; Lin, W.; Khor, T. O.; Conney, A. H.; Tony Kong, A. N. Inhibition of 7,12-Dimethylbenz(a)anthracene-Induced Skin Tumorigenesis in C57BL/6 Mice by Sulforaphane Is Mediated by Nuclear Factor E2-Related Factor 2. Cancer Res. 2006, 66, 8293-8296.
71. Jeong, W. S.; Jun, M.; Kong, A. N. Nrf2: a potential molecular target for cancer chemoprevention by natural compounds. Antioxid. Redox. Signal 2006, 8, 99-106.
72. Dinkova-Kostova, A. T.; Holtzclaw, W. D.; Kensler, T. W. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol. 2005, 18, 1779-1791.
73. McMahon, M.; Itoh, K.; Yamamoto, M.; Hayes, J. D. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J. Biol. Chem. 2003, 278, 21592-21600.
74. Kobayashi, A.; Kang, M. I.; Okawa, H.; Ohtsuji, M.; Zenke, Y.; Chiba, T.; Igarashi, K.; Yamamoto, M. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell Biol. 2004, 24, 7130-7139.
75. Kobayashi, M.; Yamamoto, M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. Antioxid. Redox. Signal 2005, 7, 385-394.
76. Velichkova, M.; Hasson, T. Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol. Cell Biol. 2005, 25, 4501-4513.
77. Itoh, K.; Wakabayashi, N.; Katoh, Y.; Ishii, T.; Igarashi, K.; Engel, J. D.; Yamamoto, M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999, 13, 76-86.
78. Dinkova-Kostova, A. T.; Holtzclaw, W. D.; Cole, R. N.; Itoh, K.; Wakabayashi, N.; Katoh, Y.; Yamamoto, M.; Talalay, P. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. USA 2002, 99, 11908-11913.
79. Kobayashi, A.; Kang, M. I.; Watai, Y.; Tong, K. I.; Shibata, T.; Uchida, K.; Yamamoto, M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell Biol. 2006, 26, 221-229.
80. Hong, F.; Freeman, M. L.; Liebler, D. C. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem. Res. Toxicol. 2005, 18, 1917-1926.
81. Hong, F.; Sekhar, K. R.; Freeman, M. L.; Liebler, D. C. Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation. J. Biol. Chem. 2005, 280, 31768-31775.
82. Bloom, D. A.; Jaiswal, A. K. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J. Biol. Chem. 2003, 278, 44675-44682.
83. Cullinan, S. B.; Zhang, D.; Hannink, M.; Arvisais, E.; Kaufman, R. J.; Diehl, J. A. Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol. Cell Biol. 2003, 23, 7198-7209.
84. Keum, Y. S.; Yu, S.; Chang, P. P.; Yuan, X.; Kim, J. H.; Xu, C.; Han, J.; Agarwal, A.; Kong, A. N. Mechanism of Action of Sulforaphane: Inhibition of p38 Mitogen-Activated Protein Kinase Isoforms Contributing to the Induction of Antioxidant Response Element-Mediated Heme Oxygenase-1 in Human Hepatoma HepG2 Cells. Cancer Res. 2006, 66, 8804-8813.
85. Nguyen, T.; Sherratt, P. J.; Nioi, P.; Yang, C. S.; Pickett, C. B. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J. Biol. Chem. 2005, 280, 32485-32492.
86. Jain, A. K.; Bloom, D. A.; Jaiswal, A. K. Nuclear import and export signals in control of Nrf2. J. Biol. Chem. 2005, 280, 29158-29168.
87. Li, W.; Yu, S. W.; Kong, A. N. Nrf2 Possesses a Redox-sensitive NES in the Neh5 transactivation Domain. J. Biol. Chem. 2006, 281, 27251-63.
88. Li, W.; Jain, M. R.; Chen, C.; Yue, X.; Hebbar, V.; Zhou, R.; Kong, A. N. Nrf2 Possesses a redox-insensitive nuclear export signal overlapping with the leucine zipper motif. J. Biol. Chem. 2005, 280, 28430-28438.
89. Xu, C.; Yuan, X.; Pan, Z.; Shen, G.; Kim, J. H.; Yu, S.; Khor, T. O.; Li, W.; Ma, J.; Kong, A. N. Mechanism of action of isothiocyanates: the induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2. Mol. Cancer Ther. 2006, 5, 1918-1926.
90. Yuan, X.; Xu, C.; Pan, Z.; Keum, Y. S.; Kim, J. H.; Shen, G.; Yu, S.; Oo, K. T.; Ma, J.; Kong, A. N. Butylated hydroxyanisole regulates ARE-mediated gene expression via Nrf2 coupled with ERK and JNK signaling pathway in HepG2 cells. Mol. Carcinog. 2006, 45(11), 841-850.
91. Salazar, M.; Rojo, A. I.; Velasco, D.; de Sagarra, R. M.; Cuadrado, A. Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2. J. Biol. Chem. 2006, 281, 14841-14851.
92. Jain, A. K.; Jaiswal, A. K. Phosphorylation of tyrosine 568 controls nuclear export of Nrf2. J. Biol. Chem. 2006, 281, 12132-12142.
93. Lin, W.; Shen, G.; Yuan, X.; Jain, M. R.; Yu, S.; Zhang, A.; Chen, J. D.; Kong, A. N. Regulation of Nrf2 transactivation domain activity by p160 RAC3/SRC3 and other nuclear co-regulators. J. Biochem. Mol. Biol. 2006, 39, 304-310.
94. Borowski, E.; Bontemps-Gracz, M. M.; Piwkowska, A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim. Pol. 2005, 52, 609-627.
95. Dietrich, C. G.; de Waart, D. R.; Ottenhoff, R.; Bootsma, A. H.; van Gennip, A. H.; Elferink, R. P. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis 2001, 22, 805-811.
96. Liu, J.; Liu, Y.; Powell, D. A.; Waalkes, M. P.; Klaassen, C. D. Multidrug-resistance mdr1a/1b double knockout mice are more sensitive than wild type mice to acute arsenic toxicity, with higher arsenic accumulation in tissues. Toxicology 2002, 170, 55-62.
97. Clifford, S. C.; Neal, D. E.; Lunec, J. High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens? Carcinogenesis 1996, 17, 601-604.
98. Gotoh, S.; Todaka, N.; Yan, Y.; Fukamachi, Y.; Abe, T.; Higashi, K. Studies on the multidrug resistance gene expression in the livers of rats associated with different susceptibility of hepatocarcinogenesis. J. Uoeh. 1999, 21, 265-276.
99. Lorico, A.; Nesland, J.; Emilsen, E.; Fodstad, O.; Rappa, G. Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice. Toxicology 2002, 171, 201-205.
100. Leslie, E. M.; Ito, K.; Upadhyaya, P.; Hecht, S. S.; Deeley, R. G.; Cole, S. P. Transport of the beta -O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1). Requirement for glutathione or a non-sulfur-containing analog. J. Biol. Chem. 2001, 276, 27846-27854.
101. Morrow, C. S.; Smitherman, P. K.; Townsend, A. J. Role of multidrug-resistance protein 2 in glutathione S-transferase P1-1-mediated resistance to 4-nitroquinoline 1-oxide toxicities in HepG2 cells. Mol. Carcinog. 2000, 29, 170-178.
102. Vlaming, M. L.; Mohrmann, K.; Wagenaar, E.; de Waart, D. R.; Elferink, R. P.; Lagas, J. S.; van Tellingen, O.; Vainchtein, L. D.; Rosing, H.; Beijnen, J. H.; Schellens, J. H.; Schinkel, A. H. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J. Pharmacol. Exp. Ther. 2006, 318, 319-327.
103. Hong, J.; Lambert, J. D.; Lee, S. H.; Sinko, P. J.; Yang, C. S. Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites. Biochem. Biophys. Res. Commun. 2003, 310, 222-227.
104. Shen, G.; Xu, C.; Hu, R.; Jain, M. R.; Gopalkrishnan, A.; Nair, S.; Huang, M. T.; Chan, J. Y.; Kong, A. N. Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and small intestine by cancer chemopreventive agent curcumin. Mol. Cancer Ther. 2006, 5, 39-51.
105. Thornalley, P. J. Isothiocyanates: mechanism of cancer chemopreventive action. Anticancer Drugs 2002, 13, 331-338.
106. Ratnasinghe, D.; Daschner, P. J.; Anver, M. R.; Kasprzak, B. H.; Taylor, P. R.; Yeh, G. C.; Tangrea, J. A. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res. 2001, 21, 2141-2147.
107. Jigorel, E.; Le Vee, M.; Boursier-Neyret, C.; Parmentier, Y.; Fardel, O. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab. Dispos. 2006, 34(10), 1756-1763.
108. Burt, R. K.; Thorgeirsson, S. S. Coinduction of MDR-1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J. Natl. Cancer Inst. 1988, 80, 1383-1386.
109. Maher, J. M.; Cheng, X.; Slitt, A. L.; Dieter, M. Z.; Klaassen, C. D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 2005, 33, 956-962.
110. Cheng, X.; Maher, J.; Dieter, M. Z.; Klaassen, C. D. Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. Drug Metab. Dispos. 2005, 33, 1276-1282.
111. Stockel, B.; Konig, J.; Nies, A. T.; Cui, Y.; Brom, M.; Keppler, D. Characterization of the 5′-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison withthe multidrug resistance protein 3 (MRP3) gene. Eur. J. Biochem. 2000, 267, 1347-1358.
112. Klaassen, C. D.; Slitt, A. L. Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 2005, 6, 309-328.
113. Huwyler, J.; Wright, M. B.; Gutmann, H.; Drewe, J. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr. Drug Metab. 2006, 7, 119-126.
114. Cheng, X.; Klaassen, C. D. Regulation of mRNA Expression of Xenobiotic Transporters by the Pregnane-X Receptor (PXR) in Mouse Liver, Kidney, and Intestine. Drug Metab. Dispos. 2006, 34, 1863-7.
115. Kauffmann, H. M.; Pfannschmidt, S.; Zoller, H.; Benz, A.; Vorderstemann, B.; Webster, J. I.; Schrenk, D. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 2002, 171, 137-146.
116. Teng, S.; Jekerle, V.; Piquette-Miller, M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 2003, 31, 1296-1299.
117. Pfrunder, A.; Gutmann, H.; Beglinger, C.; Drewe, J. Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines. J. Pharm. Pharmacol. 2003, 55, 59-66.
118. Kast, H. R.; Goodwin, B.; Tarr, P. T.; Jones, S. A.; Anisfeld, A. M.; Stoltz, C. M.; Tontonoz, P.; Kliewer, S.; Willson, T. M.; Edwards, P. A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277, 2908-2915.
119. Zhang, Y.; Callaway, E. C. High cellular accumulation of sulphoraphane, a dietary anticarcinogen, is followed by rapid transporter-mediated export as a glutathione conjugate. Biochem. J. 2002, 364, 301-307.
120. Hayashi, A.; Suzuki, H.; Itoh, K.; Yamamoto, M.; Sugiyama, Y. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem. Biophys. Res. Commun. 2003, 310, 824-829.
121. Di Pietro, A.; Conseil, G.; Perez-Victoria, J. M.; Dayan, G.; Baubichon-Cortay, H.; Trompier, D.; Steinfels, E.; Jault, J. M.; de Wet, H.; Maitrejean, M.; Comte, G.; Boumendjel, A.; Mariotte, A. M.; Dumontet, C.; McIntosh, D. B.; Goffeau, A.; Castanys, S.; Gamarro, F.; Barron, D. Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol. Life Sci. 2002, 59, 307-322.
122. Zhang, S.; Morris, M. E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 2003, 304, 1258-1267.
123. Wang, E. J.; Casciano, C. N.; Clement, R. P.; Johnson, W. W. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm. Res. 2001, 18, 432-438.
124. Takanaga, H.; Ohnishi, A.; Yamada, S.; Matsuo, H.; Morimoto, S.; Shoyama, Y.; Ohtani, H.; Sawada, Y. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J. Pharmacol. Exp. Ther. 2000, 293, 230-236.
125. Nabekura, T.; Kamiyama, S.; Kitagawa, S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem. Biophys. Res. Commun. 2005, 327, 866-870.
126. Talalay, P.; De Long, M. J.; Prochaska, H. J. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc. Natl. Acad. Sci. USA 1988, 85, 8261-8265.
127. Nho, C. W.; Jeffery, E. The synergistic upregulation of phase II detoxification enzymes by glucosinolate breakdown products in cruciferous vegetables. Toxicol. Appl. Pharmacol. 2001, 174, 146-152.
128. Auyeung, D. J.; Kessler, F. K.; Ritter, J. K. Mechanism of rat UDP-glucuronosyltransferase 1A6 induction by oltipraz: evidence for a contribution of the Aryl hydrocarbon receptor pathway. Mol. Pharmacol. 2003, 63, 119-127.
129. Miao, W.; Hu, L.; Kandouz, M.; Batist, G. Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element. Mol. Pharmacol. 2003, 64, 346-354.
130. Kohle, C.; Bock, K. W. Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals in relation to chemoprevention. Biochem. Pharmacol. 2006, 72, 795-805.
131. Bock, K. W.; Eckle, T.; Ouzzine, M.; Fournel-Gigleux, S. Coordinate induction by antioxidants of UDP-glucuronosyltransferase UGT1A6 and the apical conjugate export pump MRP2 (multidrug resistance protein 2) in Caco-2 cells. Biochem. Pharmacol. 2000, 59, 467-470.
132. Perocco, P.; Bronzetti, G.; Canistro, D.; Valgimigli, L.; Sapone, A.; Affatato, A.; Pedulli, G. F.; Pozzetti, L.; Broccoli, M.; Iori, R.; Barillari, J.; Sblendorio, V.; Legator, M. S.; Paolini, M.; Abdel-Rahman, S. Z. Glucoraphanin, the bioprecursor of the widely extolled chemopreventive agent sulforaphane found in broccoli, induces phase-I xenobiotic metabolizing enzymes and increases free radical generation in rat liver. Mutat. Res. 2006, 595, 125-136.
133. Kassahun, K.; Davis, M.; Hu, P.; Martin, B.; Baillie, T. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chem. Res. Toxicol. 1997, 10, 1228-1233.
134. Miao, W.; Hu, L.; Scrivens, P. J.; Batist, G. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J. Biol. Chem. 2005, 280, 20340-20348.
135. Zhang, Q.; Bae, Y.; Kemper, J. K.; Kemper, B. Analysis of multiple nuclear receptor binding sites for CAR/RXR in the phenobarbital responsive unit of CYP2B2. Arch. Biochem. Biophys. 2006, 451, 119-127.
136. Idle, J. R.; Armstrong, M.; Boddy, A. V.; Boustead, C.; Cholerton, S.; Cooper, J.; Daly, A. K.; Ellis, J.; Gregory, W.; Hadidi, H.; et al. The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 1992, 2, 246-258.
137. Vineis, P. The relationship between polymorphisms of xenobiotic metabolizing enzymes and susceptibility to cancer. Toxicology 2002, 181-182, 457-462.
138. Seow, A.; Vainio, H.; Yu, M. C. Effect of glutathione-S-transferase polymorphisms on the cancer preventive potential of isothiocyanates: an epidemiological perspective. Mutat. Res. 2005, 592, 58-67.
139. Schwarz, D.; Kisselev, P.; Roots, I. CYP1A1 genotype-selective inhibition of benzo[a]pyrene activation by quercetin. Eur. J. Cancer 2005, 41, 151-158.
140. Cauchi, S.; Han, W.; Kumar, S. V.; Spivack, S. D. Haplotype-environment interactions that regulate the human glutathione S-transferase P1 promoter. Cancer Res. 2006, 66, 6439-6448.
141. Okey, A. B.; Boutros, P. C.; Harper, P. A. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. Pharmacogenet. Genomics 2005, 15, 371-379.
142. Yamamoto, T.; Yoh, K.; Kobayashi, A.; Ishii, Y.; Kure, S.; Koyama, A.; Sakamoto, T.; Sekizawa, K.; Motohashi, H.; Yamamoto, M. Identification of polymorphisms in the promoter region of the human NRF2 gene. Biochem. Biophys. Res. Commun. 2004, 321, 72-79.
143. Padmanabhan, B.; Tong, K. I.; Ohta, T.; Nakamura, Y.; Scharlock, M.; Ohtsuji, M.; Kang, M. I.; Kobayashi, A.; Yokoyama, S.; Yamamoto, M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 2006, 21, 689-700.
144. Gescher, A. J.; Sharma, R. A.; Steward, W. P. Cancer chemoprevention by dietary constituents: a tale of failure and promise. Lancet Oncol. 2001, 2, 371-379.
145. Sporn, M. B.; Liby, K. T. Cancer chemoprevention: scientific promise, clinical uncertainty. Nat. Clin. Pract. Oncol. 2005, 2, 518-525.